Literature DB >> 21351489

[Effects of dihydroxy-stilbene compound Vam3 on airway inflammation, expression of ICAM-1, activities of NF-kappaB and MMP-9 in asthmatic mice].

Li Yang1, Chun-suo Yao, Zhi-yuan Wu, Ling-ling Xuan, Jin-ye Bai, Gui-fang Cheng, Mao Lin, Ming-chun Wen, Qi Hou.   

Abstract

The aim of the present study is to investigate the effects of Vam3 which is one of the dihydroxystilbene compounds on expressions of ICAM-1 in the lungs of OVA-induced asthmatic mice and the mechanisms of anti-airway inflammation. Balb/c mice were challenged with OVA inhalation. Lung tissues were stained with Mayer's hematoxylin and eosin for histopathologic examination. The expression of ICAM-1 in the lungs of mice was analyzed by Western blotting and immunohistochemistry method. The NF-kappaB activities were detected by NF-kappaB-luc reporter genetic transient transfection method. The activities of MMP-9 induced by LPS, TNF-alpha and PMA in THP-1 cells were determined by gelatin zymography method. The results showed that Vam3 could inhibit the expression of ICAM-1 in the OVA-induced mouse model. In addition, Vam3 could significantly suppress the activities of NF-kappaB in A549 cells and MMP-9 in THP-1 cells induced by LPS, TNF-alpha and PMA. These results suggested that Vam3 could alleviate the asthmatic inflammation by decreasing ICAM-1 expression in asthmatic mice, down regulating NF-kappaB and MMP-9 activities. Compound Vam3 showed inhibitory effects on inflammatory signal pathways involved in asthma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21351489

Source DB:  PubMed          Journal:  Yao Xue Xue Bao        ISSN: 0513-4870


  8 in total

1.  Vam3, a derivative of resveratrol, attenuates cigarette smoke-induced autophagy.

Authors:  Ji Shi; Ning Yin; Ling-ling Xuan; Chun-suo Yao; Ai-min Meng; Qi Hou
Journal:  Acta Pharmacol Sin       Date:  2012-06-18       Impact factor: 6.150

2.  Recombinant rat CC16 protein inhibits LPS-induced MMP-9 expression via NF-κB pathway in rat tracheal epithelial cells.

Authors:  Min Pang; Hailong Wang; Ji-Zhong Bai; Dawei Cao; Yi Jiang; Caiping Zhang; Zhihong Liu; Xinri Zhang; Xiaoyun Hu; Jianying Xu; Yongcheng Du
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-24

3.  Vam3, a resveratrol dimer, inhibits cigarette smoke-induced cell apoptosis in lungs by improving mitochondrial function.

Authors:  Ling-Ling Xuan; Ji Shi; Chun-Suo Yao; Jin-Ye Bai; Feng Qu; Jin-Lan Zhang; Qi Hou
Journal:  Acta Pharmacol Sin       Date:  2014-04-21       Impact factor: 6.150

4.  A combined experimental and computational study of Vam3, a derivative of resveratrol, and Syk interaction.

Authors:  Ming Jiang; Renping Liu; Ying Chen; Qisheng Zheng; Saijun Fan; Peixun Liu
Journal:  Int J Mol Sci       Date:  2014-09-25       Impact factor: 5.923

5.  Amurensin H, a Derivative From Resveratrol, Ameliorates Lipopolysaccharide/Cigarette Smoke-Induced Airway Inflammation by Blocking the Syk/NF-κB Pathway.

Authors:  Yannan Fan; Ziqian Zhang; Chunsuo Yao; Jinye Bai; Hui Yang; Pei Ma; Yiyao Fan; Shuyi Li; Jiqiao Yuan; Mingbao Lin; Qi Hou
Journal:  Front Pharmacol       Date:  2019-10-04       Impact factor: 5.810

6.  Chondroprotective and anti-inflammatory effects of amurensin H by regulating TLR4/Syk/NF-κB signals.

Authors:  Pei Ma; Lifeng Yue; Hui Yang; Yannan Fan; Jinye Bai; Shuyi Li; Jiqiao Yuan; Ziqian Zhang; Chunsuo Yao; Mingbao Lin; Qi Hou
Journal:  J Cell Mol Med       Date:  2019-12-25       Impact factor: 5.310

7.  Pharmacokinetic analysis and tissue distribution of Vam3 in the rat by a validated LC-MS/MS method.

Authors:  Ruixia Zhang; Ping Mao; Tingting Zhang; Chen Ma; Bo Jin; Tong Li
Journal:  Acta Pharm Sin B       Date:  2015-04-08       Impact factor: 11.413

8.  Vam3, a Compound Derived from Vitis amurensis Rupr., Attenuated Colitis-Related Tumorigenesis by Inhibiting NF-κB Signaling Pathway.

Authors:  Lingling Xuan; Rentao Jiang; Zhiyuan Wu; Honggan Yi; Chunsuo Yao; Qi Hou; Chunfeng Qu
Journal:  Front Pharmacol       Date:  2016-09-13       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.